Clinical Trial News and Research

RSS

Chemoradioimmunotherapy for advanced breast cancer

A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital

8 Jul 2004

Endo announces agreement With FDA for new trial design of oxymorphone extended-release tablets

Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration

7 Jul 2004

Combining targeted immunotherapy with chemotherapy and radiation therapy to successfully kill metastatic tumour cells

A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo and radioresistant mechanisms was by presented by Dr. John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital

7 Jul 2004

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

The development of simple and inexpensive generic fixed-dose combined therapies appears the most suitable solution for making possible this access to treatments in developing countries with meagre resources.

3 Jul 2004

Drop in systolic blood pressure may indicate imminent likelihood of Alzheimer’s disease or dementia

Journal of the American Heart Association reports that a significant drop in systolic blood pressure may indicate imminent likelihood of Alzheimer’s disease or dementia in some elderly people.

2 Jul 2004

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

Combination therapy with three generic antiretroviral drugs in a single tablet has been validated for the first time in an open clinical study in a developing country. Follow-up of 60 patients treated in Yaoundé, Cameroon, has demonstrated the excellent efficacy and safety of a generic fixed-dose combination.

2 Jul 2004

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

One of the strategies adopted consists in utilizing combinations of fixed doses of generic antiretrovirals, involving three medicinal drugs of two different classes in the same tablet.

2 Jul 2004

Physical activity cuts risk of depression in children

Students who increase their physical activity during their middle-school years have fewer symptoms of depression, according to a new study.

1 Jul 2004

Aspartame in foods and beverages can help with weight loss and long-term control of body weight

Contrary to the hypothesis of two Purdue University researchers just published in the International Journal of Obesity, several studies have shown that the use of aspartame in foods and beverages can help with weight loss and long-term control of body weight and does not increase hunger or food intake in children or adults.

30 Jun 2004

Alcon updates filing status of RETAANE® new drug application

Alcon, Inc. has announced that it has filed the second portion of its “rolling” New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for RETAANE® 15mg (anecortave acetate for depot suspension)

30 Jun 2004

About 40 percent of U.S. adults ages 40 to 74 — millions of whom are Hispanic or Latino — currently have pre-diabetes

About 40 percent of U.S. adults ages 40 to 74 — millions of whom are Hispanic or Latino — currently have pre-diabetes, a condition that raises a person's risk of developing type 2 diabetes, heart disease, and stroke.

29 Jun 2004

Immune modulation therapy, latest treatment for people with chronic heart failure

Here is the latest treatment for people with chronic heart failure: a nurse draws blood from the patient, runs that blood through a machine, superheating and “stressing” the blood, and then, injects it back into the patient.

29 Jun 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Alzheimer’s Society expresses concern over new study on dementia drug effectiveness, published in The Lancet

The Alzheimer’s Society has expressed serious concern at the interpretation of a new study into the effectiveness of drugs for dementia, published in The Lancet.

25 Jun 2004

Answers to childhood asthma may be in herbal medicine

A clinical trial to determine whether a herbal medicine can ease the symptoms of asthma in children is underway at RMIT University.

24 Jun 2004

Drug companies spend about 37% of their overall R&D budgets on clinical affairs

Over the last decade, clinical services industry growth has exploded. Today, study sponsors dedicate significant portions of their budgets to CROs, SMOs and patient recruiters to access the expertise needed to speed trials to safe and successful fruition.

23 Jun 2004

Paclitaxel analog kills more cancer cells than natural product

Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.

21 Jun 2004

Pharmaxis completes interim analysis on Bronchitol study

Sydney-based pharmaceutical company Pharmaxis Ltd has conducted an interim analysis on the Phase IIb clinical trial evaluating Bronchitol™ in patients with the respiratory condition bronchiectasis.

21 Jun 2004

Harmless virus known as GBV-C slows the progression of HIV

Iowa City Veterans Affairs (VA) Medical Center and University of Iowa (UI) researchers have unlocked part of the mystery of how a harmless virus known as GBV-C slows the progression of HIV and prolongs survival for many patients.

17 Jun 2004

Genetically engineered thyroid stimulating hormone destroys tissue that often remains after thyroidectomy

A new approach to therapy can avoid most of the debilitating effects of preparing for critical, postsurgical treatment for patients with thyroid cancer, according to an international study led by researchers from Johns Hopkins and the University of Pisa.

16 Jun 2004

Clinical Trial News and Research

Chemoradioimmunotherapy for advanced breast cancer

Endo announces agreement With FDA for new trial design of oxymorphone extended-release tablets

Combining targeted immunotherapy with chemotherapy and radiation therapy to successfully kill metastatic tumour cells

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

Drop in systolic blood pressure may indicate imminent likelihood of Alzheimer’s disease or dementia

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

Physical activity cuts risk of depression in children

Aspartame in foods and beverages can help with weight loss and long-term control of body weight

Alcon updates filing status of RETAANE® new drug application

About 40 percent of U.S. adults ages 40 to 74 — millions of whom are Hispanic or Latino — currently have pre-diabetes

Immune modulation therapy, latest treatment for people with chronic heart failure

Exelixis files new drug application for a proprietary novel anticancer compound

Alzheimer’s Society expresses concern over new study on dementia drug effectiveness, published in The Lancet

Answers to childhood asthma may be in herbal medicine

Drug companies spend about 37% of their overall R&D budgets on clinical affairs

Paclitaxel analog kills more cancer cells than natural product

Pharmaxis completes interim analysis on Bronchitol study

Harmless virus known as GBV-C slows the progression of HIV

Genetically engineered thyroid stimulating hormone destroys tissue that often remains after thyroidectomy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News